Skip to main content
SpringerLink
Log in

Continuous Production of Fenofibrate Solid Lipid Nanoparticles by Hot-Melt Extrusion Technology: a Systematic Study Based on a Quality by Design Approach

  • Research Article
  • Theme: Develop Enabling Technologies for Delivering Poorly Water Soluble Drugs: Current Status and Future Perspectives
  • Published:
The AAPS Journal Aims and scope Submit manuscript

Abstract

This contribution describes a continuous process for the production of solid lipid nanoparticles (SLN) as drug-carrier systems via hot-melt extrusion (HME). Presently, HME technology has not been used for the manufacturing of SLN. Generally, SLN are prepared as a batch process, which is time consuming and may result in variability of end-product quality attributes. In this study, using Quality by Design (QbD) principles, we were able to achieve continuous production of SLN by combining two processes: HME technology for melt-emulsification and high-pressure homogenization (HPH) for size reduction. Fenofibrate (FBT), a poorly water-soluble model drug, was incorporated into SLN using HME-HPH methods. The developed novel platform demonstrated better process control and size reduction compared to the conventional process of hot homogenization (batch process). Varying the process parameters enabled the production of SLN below 200 nm. The dissolution profile of the FBT SLN prepared by the novel HME-HPH method was faster than that of the crude FBT and a micronized marketed FBT formulation. At the end of a 5-h in vitro dissolution study, a SLN formulation released 92–93% of drug, whereas drug release was approximately 65 and 45% for the marketed micronized formulation and crude drug, respectively. Also, pharmacokinetic study results demonstrated a statistical increase in Cmax, Tmax, and AUC0–24 h in the rate of drug absorption from SLN formulations as compared to the crude drug and marketed micronized formulation. In summary, the present study demonstrated the potential use of hot-melt extrusion technology for continuous and large-scale production of SLN.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Patil A, Pokharkar V. Single step spray drying method to develop proliposomes for inhalation: a systematic study based on quality by design approach. Pulm Pharmacol Ther. 2014;27:197–207.

    Article  Google Scholar 

  2. Basalious EB, El-Sebaie W, El-Gazayerly O. Application of pharmaceutical QbD for enhancement of the solubility and dissolution of a class II BCS drug using polymeric surfactants and crystallization inhibitors: development of controlled-release tablets. AAPS Pharm Sci Technol. 2011;12:799–810.

    Article  CAS  Google Scholar 

  3. Maltesen MJ, Bjerregaard S, Hovgaard L, Havelund S, Weert M. Quality by design spray drying of insulin intended for inhalation. Eur J Pharm Biopharm. 2008;70:828–38.

    Article  CAS  PubMed  Google Scholar 

  4. Yerlikaya F, Ozgen A, Vural I, Guven O, Karaagaoglu E, et al. Development and evaluation of paclitaxel nanoparticles using a quality-by-design approach. J Pharm Sci. 2013;102:3748–61.

    Article  CAS  PubMed  Google Scholar 

  5. US FDA Guidance for industry: PAT—a framework for innovative pharmaceutical development, manufacturing, and quality assurance. Maryland: Silver Spring; 2004.

  6. Hanafy A, Spahn-Langguth H, Vergnault G, Grenier P, Tubic Grozdanis M, et al. Pharmacokinetic evaluation of oral fenofibrate nanosuspensions and SLN in comparison to conventional suspensions of micronized drug. Adv Drug Deliv Rev. 2007;59:419–26.

    Article  CAS  PubMed  Google Scholar 

  7. Rao GC, Kumar MS, Mathivanan N, Rao ME. Nanosuspensions as the most promising approach in nanoparticulate drug delivery systems. Pharmazie. 2004;59:5–9.

    CAS  PubMed  Google Scholar 

  8. Patil H, Kulkarni V, Majumdar S, Repka MA. Continuous manufacturing of solid lipid nanoparticles by hot melt extrusion. Int J Pharm. 2014;471:153–6.

    Article  CAS  PubMed  Google Scholar 

  9. Niu X, Wan L, Hou Z, Wang T, Sun C, et al. Mesoporous carbon as a novel drug carrier of fenofibrate for enhancement of the dissolution and oral bioavailability. Int J Pharm. 2013;452:382–9.

    Article  CAS  PubMed  Google Scholar 

  10. Sanganwar GP, Gupta RP. Dissolution-rate enhancement of fenofibrate by adsorption onto silica using supercritical carbon dioxide. Int J Pharm. 2008;360:213–8.

    Article  CAS  PubMed  Google Scholar 

  11. Wishart DS, Konx C, Guo AC, Shrivastava S, Hassanali M, et al. Drug bank: a comprehensive resource for in silicon drug discovery and exploration. Nucleic Acids Res. 2006;1:D668–72.

    Article  Google Scholar 

  12. Ming-Thau S, Ching-Min Y, Sokoloski TD. Characterization and dissolution of fenofibrate solid dispersion systems. Int J Pharm. 1994;103:137–46.

    Article  Google Scholar 

  13. Mehnert W, Mader K. Solid lipid nanoparticles: production, characterization and applications. Adv Drug Deliv Rev. 2001;47:165–96.

    Article  CAS  PubMed  Google Scholar 

  14. Crowley MM, Zhang F, Repka MA, Thumma S, Upadhye SB, Battu SK, et al. Pharmaceutical applications of hot-melt extrusion: part I. Drug Dev Ind Pharm. 2007;33(9):909–26.

    Article  CAS  PubMed  Google Scholar 

  15. Repka MA, Battu SK, Upadhye SB, Thumma S, Crowley MM, et al. Pharmaceutical applications of hot-melt extrusion: part II. Drug Dev Ind Pharm. 2007;33:1043–57.

    Article  CAS  PubMed  Google Scholar 

  16. Breitenbach J. Melt extrusion: from process to drug delivery technology. Eur J Pharm Biopharm. 2002;54:107–17.

    Article  CAS  PubMed  Google Scholar 

  17. Maniruzzaman M, Boateng JS, Snowde MJ, Douroumis D. A review of hot-melt extrusion: process technology to pharmaceutical products. ISRN Pharm. 2012;1–9.

  18. Das S, Ng WK, Kanaujia P, Kim S, Tan RB. Formulation design, preparation and physicochemical characterizations of solid lipid nanoparticles containing a hydrophobic drug: effects of process variables. Colloids Surf B: Biointerfaces. 2011;88:483–9.

    Article  CAS  PubMed  Google Scholar 

  19. Dong Y, Ng WK, Shen S, Kim S, Tan RB. Solid lipid nanoparticles: continuous and potential large-scale nanoprecipitation production in static mixers. Colloids Surf B: Biointerfaces. 2012;94:68–72.

    Article  CAS  PubMed  Google Scholar 

  20. Raza K, Singh B, Singal P, Wadhwa S, Katare OP. Systematically optimized biocompatible isotretinoin-loaded solid lipid nanoparticles (SLNs) for topical treatment of acne. Colloids Surf B: Biointerfaces. 2013;105:67–74.

    Article  CAS  PubMed  Google Scholar 

  21. Shah RM, Malherbe F, Eldridge D, Palombo EA, Harding IH. Physicochemical characterization of solid lipid nanoparticles (SLNs) prepared by a novel microemulsion technique. J Colloid Interface Sci. 2014;428:286–94.

    Article  CAS  PubMed  Google Scholar 

  22. Luo Y, Chen D, Ren L, Zhao X, Qin J. Solid lipid nanoparticles for enhancing vinpocetine's oral bioavailability. J Control Release. 2006;114:53–9.

    Article  CAS  PubMed  Google Scholar 

  23. Wang S, Chen T, Chen R, Hu Y, Chen M, et al. Emodin loaded solid lipid nanoparticles: preparation, characterization and antitumor activity studies. Int J Pharm. 2012;430:238–46.

    Article  CAS  PubMed  Google Scholar 

  24. ICH Q 1 A (R2). Stability testing of new drug substances and products. http://www.emea.eu.int/pdfs/human/ich/273699en.pdf

  25. Hu L, Tang X, Cui F. Solid lipid nanoparticles (SLNs) to improve oral bioavailability of poorly soluble drugs. J Pharm Pharmacol. 2004;56:1527–35.

    Article  CAS  PubMed  Google Scholar 

  26. Liu J, Hu W, Chen H, Ni Q, Xu H, et al. Isotretinoin-loaded solid lipid nanoparticles with skin targeting for topical delivery. Int J Pharm. 2007;328:191–5.

    Article  CAS  PubMed  Google Scholar 

  27. Rahman Z, Zidan AS, Habib MJ, Khan MA. Understanding the quality of protein loaded PLGA nanoparticles variability by Plackett-Burman design. Int J Pharm. 2010;389(1–2):186–94.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  28. Huang QP, Wang JX, Zhang ZB, Shen ZG, Chen JF, et al. Preparation of ultrafine fenofibrate powder by solidification process from emulsion. Int J Pharm. 2009;368:160–4.

    Article  CAS  PubMed  Google Scholar 

  29. Van Drooge DJ, Hinrichs WL, Frijlink HW. Anomalous dissolution behaviour of tablets prepared from sugar glass-based solid dispersions. J Control Release. 2004;97:441–52.

    Article  PubMed  Google Scholar 

  30. Mosharraf M, NyatrÖm C. The effect of particle size and shape on the surface specific dissolution rate of microsized practically insoluble drugs. Int J Pharm. 1995;122:35–47.

    Article  CAS  Google Scholar 

  31. Müller RH, Peters K. Nanosuspensions for the formulation of poorly soluble drugs: I. Preparation by a size-reduction technique. Int J Pharm. 1998;160:229–37.

    Article  Google Scholar 

  32. Jia Z, Lin P, Xiang Y, Wang X, Wang J, Zhang X, et al. A novel nanomatrix system consisted of colloidal silica and pH-sensitive polymethylacrylate improves the oral bioavailability of fenofibrate. Eur J Pharm Biopharm. 2011;79(1):126–34.

    Article  CAS  PubMed  Google Scholar 

  33. Borkar N, Xia D, Holm R, Gan Y, Mullertz A, Yang M, et al. Investigating the correlation between in vivo absorption and in vitro release of fenofibrate from lipid matrix particles in biorelevant medium. Eur J Pharm Sci. 2014;51:204–10.

    Article  CAS  PubMed  Google Scholar 

  34. Noyes AA, Whitney WR. The rate of solution of solid substances in their own solutions. J Am Chem Soc. 1897;19:930–4.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pharmaceutics & Drug Delivery, University of Mississippi, University, Mississippi, 38677, USA

    Hemlata Patil, Xin Feng, Xingyou Ye, Soumyajit Majumdar & Michael A. Repka

  2. Pii Center for Pharmaceutical Technology, School of Pharmacy, University of Mississippi, University, Mississippi, 38677, USA

    Michael A. Repka

Authors
  1. Hemlata Patil
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Xin Feng
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Xingyou Ye
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Soumyajit Majumdar
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Michael A. Repka
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michael A. Repka.

Additional information

Guest Editors: Ping Gao and Lawrence Yu

Electronic Supplementary Material

Below is the link to the electronic supplementary material.

ESM 1

(DOCX 1.20 mb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Patil, H., Feng, X., Ye, X. et al. Continuous Production of Fenofibrate Solid Lipid Nanoparticles by Hot-Melt Extrusion Technology: a Systematic Study Based on a Quality by Design Approach. AAPS J 17, 194–205 (2015). https://doi.org/10.1208/s12248-014-9674-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1208/s12248-014-9674-8

KEY WORDS

Search

Navigation